Speaking about his experience at iPHEX 2024 and business prospects, a team spokesperson stated:

“Soft gelatin capsule formulations have a bright future. We have received multiple enquiries for CRAMS opportunities in soft gel capsule formulations. The CRAMS market demand is high due to the scarcity of skilled quality players in this formulation segment. The core strengths of DCAL are its science-based approach towards product development, regulatory-sufficiency documentation with an international standard manufacturing facility, and support staff with in-depth technical knowledge and experience in soft gel capsules technical know-how. Our core development strength is converting very poorly soluble API into soft gel formulation to enhance bioavailability.

 

As a new entrant in the soft gel capsule formulation business, we keep working towards the diversification of product portfolios in different therapeutic ranges with a scientific approach. With a wide diversified range of products, we want our customers to meet the market needs and demands. At iPHEX, we were proud to connect with overseas buyers and Indian visitors who are familiar with the Dishman brand in the API business. They were very impressed with our venture into the very niche formulation category of soft gelatin capsule dosage forms CRAMS business.”